Hhlr Advisors, Ltd. Apellis Pharmaceuticals, Inc. Transaction History

Hhlr Advisors, Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $92 Million - $205 Million	-2,929,708 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $66.6 Million - $106 Million	-1,628,321 Reduced 35.72%	2,929,708 $185 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $19.2 Million - $27 Million	-470,260 Reduced 9.35%	4,558,029 $196 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $6.27 Million - $15.5 Million	350,000 Added 7.48%	5,028,289 $135 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $50.6 Million - $67.5 Million	2,098,581 Added 81.35%	4,678,289 $113 Million
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $4.48 Million - $6.94 Million	350,000 Added 15.7%	2,579,708 $50.3 Million
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $25.6 Million - $41.7 Million	2,229,708 New	2,229,708 $29.4 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.